<DOC>
	<DOCNO>NCT02952092</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy ASP1517 compare darbepoetin alfa hemodialysis chronic kidney disease patient anemia .</brief_summary>
	<brief_title>A Study Intermittent Oral Dosing ASP1517 Hemodialysis Chronic Kidney Disease Patients With Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects renal anemia receive recombinant human erythropoietin ( rHuEPO , two time weekly three time weekly ) darbepoetin alfa ( intravenous treatment ) within dos approve Japan 8 week screen assessment Mean subject 's two recent Hb value dialysis long dialysis interval Screening Period must ≥10.0 g/dL ≤12.0 g/dL Either transferrin saturation ( TSAT ) ≥ 20 % serum ferritin ≥ 100 ng/mL screen period Female subject must either : Be nonchildbearing potential : postmenopausal ( define least 1 year without menses ) prior Screening , document surgically sterile Or , childbearing potential , Agree try become pregnant study 28 day final study drug administration And negative pregnancy test Screening And , heterosexually active , agree consistently use two form highly effective form birth control ( least one must barrier method ) start Screening throughout study period continue 28 day final study drug administration . Female subject must agree breastfeed start Screening throughout study period , continue 28 day final study drug administration . Female subject must donate ovum start Screening throughout study period , continue 28 day final study drug administration . Male subject female spouse/partners childbearing potential must use two form highly effective form birth control ( least one must barrier method ) start Screening continue throughout study period , 12 week final study drug administration Male subject must donate sperm start Screening throughout study period , 12 week final study drug administration Concurrent retinal neovascular lesion untreated macular edema untreated Concurrent autoimmune disease inflammation could impact erythropoiesis History gastric/intestinal resection consider influential absorption drug gastrointestinal tract ( exclude resection gastric colon polyp ) concurrent gastroparesis Uncontrolled hypertension Concurrent congestive heart failure ( NYHA Class III high ) History hospitalization treatment stroke , myocardial infarction , pulmonary embolism within 12 week screen assessment Positive hepatitis B surface antigen ( HBsAg ) antihepatitis C virus ( HCV ) antibody screen assessment , positive human immunodeficiency virus ( HIV ) past test Concurrent form anemia renal anemia History pure red cell aplasia Having receive treatment protein anabolic hormone , testosterone enanthate , mepitiostane within 6 week screen assessment Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , total bilirubin great criterion , previous concurrent another serious liver disease screen assessment Previous current malignant tumor ( recurrence least 5 year eligible . ) Having undergone blood transfusion and/or surgical procedure consider promote anemia ( exclude shunt reconstruction surgery access blood ) and/or ophthalmological surgery within 4 week screen assessment Having undergone kidney transplantation Having previous history treatment ASP1517 History serious drug allergy include anaphylactic shock Participation another clinical study postmarketing clinical study ( include medical device ) within 12 week informed consent acquisition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ASP1517</keyword>
	<keyword>Renal anemia</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Roxadustat</keyword>
</DOC>